依达拉奉治疗急性重型颅脑损伤40例疗效分析

Effect of edaravone on patients with acute moderate and severe brain injury

目的观察依达拉奉治疗急性重型颅脑损伤的临床疗效。方法将80例急性颅脑损伤患者随机分为依达拉奉组(治疗组)和常规治疗组(对照组),每组40例。对照组予以常规治疗,包括脱水、抗感染以及依手术指征清除颅内血肿、去骨瓣减压等治疗。治疗组在对照组基础上加用依达拉奉30 mg+5%葡萄糖溶液100 ml静脉滴注,30min内滴完,2次/d,共14 d。根据格拉斯哥昏迷评分(GCS)、脑水肿程度以及格拉斯哥结果分级(GOS)评估等比较2组患者病情恢复情况。结果 (1)2组患者治疗前后GCS评分间差异均有统计学意义(P<0.05);组间比较,2组患者治疗7 d、14 d后GCS评分间差异均有统计学意义(P<0.05)。(2)治疗10 d后2组患者脑水肿程度问差异有统计学意义(P<0.01)。(3)2组患者GOS评估情况间差异有统计学意义(P<0.05)。结论急性中、重型颅脑损伤应用依达拉奉,可降低颅脑损伤后的病践程度,促进脑神经功能恢复,减轻脑水肿,且不良反应小、安全性高,值得推广使用。

Objective To evaluate the efficacy and safety of edaravone on patients with acute moderate and severe brain injury.Methods 80 patients with acute moderate and severe brain injury were divided into a trial group and a control group randomly,with 40 cases in each.Both groups received standard therapy.Meanwhile the patients in the trial group were given edaravone infusion at a dose of 30mg,twice a day,for 14 days.According to GCS,degree of cerebral edema and GOS,the recovery conditions of the patients between the two groups were compared.Results There was a significant difference in GCS before and after treatment in the two groups（P0.05）.There were also significant differences in GCS 7 days and 14 days after treatment between the two groups（P0.05）.Significant difference existed in brain edema 10 days after the treatment between the two groups（P0.01）.The difference in GOS between the two groups was found to be statistically significant（P0.05）.Conclusion The early application of edaravone for patients with acute moderate and severe brain injury can decrease the degree of disability,promote the recovery of neural function and reduce brain edema,with a quite reliable safety.